ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE and OSTEOPOROSIS

Overview

OSTEOPOROSIS is the #13 most commonly reported adverse reaction for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc.. There are 1,729 FDA adverse event reports linking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE to OSTEOPOROSIS. This represents approximately 3.8% of all 45,551 adverse event reports for this drug.

Patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE who experience osteoporosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

OSTEOPOROSIS is moderately reported among ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE users, representing a notable but not dominant share of adverse events.

Other Side Effects of ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

In addition to osteoporosis, the following adverse reactions have been reported for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE:

• BONE DENSITY DECREASED — 4,550 reports
• RENAL INJURY — 3,304 reports
• SKELETAL INJURY — 3,020 reports
• CHRONIC KIDNEY DISEASE — 2,482 reports
• TOOTH LOSS — 2,455 reports
• BONE LOSS — 2,134 reports
• OSTEONECROSIS — 2,095 reports
• RENAL FAILURE — 2,052 reports
• TOOTH INJURY — 1,970 reports
• MULTIPLE FRACTURES — 1,957 reports

Other Drugs Associated with OSTEOPOROSIS

The following drugs have also been linked to osteoporosis in FDA adverse event reports:

Does ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE cause OSTEOPOROSIS?

OSTEOPOROSIS has been reported as an adverse event in 1,729 FDA reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is OSTEOPOROSIS with ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE?

OSTEOPOROSIS accounts for approximately 3.8% of all adverse event reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, making it a notable side effect.

What should I do if I experience OSTEOPOROSIS while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE?

If you experience osteoporosis while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages